Afatinib (BIBW 2992)

Small-Molecule Targeted Anti Tumor Inhibitor API  Afatinib 
(CAS: 439081-18-2)

Chemical Information
Quick Details:

Product Name: Afatinib
Other Names:Afatinib;(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide;4-[(3-chloro-4-fluorophenyl)aMino]-6-{[4-(N,N-diMethylaMino)-1-oxo-2-buten-1-yl]aMino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline;2-ButenaMide, N-[4-[(3-chloro-4-fluorophenyl)aMino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(diMethylaMino)-, (2E)-;(S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dime;Afatinib API;Afatinib(BIBW2992MA2);Afatinib (with 1 int.)
Model No.: ATC-136
CAS No.: 439081-18-2
Molecular Formula: C24H25ClFN5O3
Molecular Weight: 485.94
Appearance: White or Nearly White Crystalline Powder
Purity: 99%+
Product Specifications: Pharmaceutical Grade
        
Product Description
Afatinib (INN; trade name Gilotrif in the US and Giotrif in Europe, previously Tomtovok and Tovok) is a drug approved in United States, Europe, Taiwan, Mexico, Chile and Japan as well as other countries for the first-line treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2).

Applications/Usage
It has received regulatory approval for use as a treatment for non-small cell lung cancer, although there is emerging evidence to support its use in other cancers such as breast cancer.

COA Report:

FEATURED PRODUCT: